Here's Why You Should Add LPCN Stock to Your Portfolio NowZacks Investment Research · Oct 8, 2026
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In CanadaBenzinga · Oct 7, 2026
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement TherapyPRNewsWire · Oct 7, 2026
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research · Sep 23, 2026
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum DepressionPRNewsWire · Sep 14, 2026
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment ConferencePRNewsWire · Sep 10, 2026Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.40 | -$0.32 | Beat |
| May 7, 2026 | -$0.51 | -$0.54 | Miss |
| Mar 9, 2026 | -$0.60 | -$0.34 | Beat |
| Nov 6, 2025 | -$0.56 | -$0.59 | Miss |
| Aug 5, 2025 | -$0.41 | -$0.41 | Beat |
| May 8, 2025 | -$0.35 | -$0.35 | Beat |